Nanoparticle Targeting CD44-Positive Cancer Cells for Site-Specific Drug Delivery in Prostate Cancer Therapy

Wen Ying Huang, Jia Ni Lin, Jer Tsong Hsieh, Shen Chieh Chou, Chih Ho Lai, Eun Jin Yun, U. Ging Lo, Rey Chen Pong, Jui Hsiang Lin, Yu Hsin Lin

Research output: Contribution to journalArticlepeer-review

73 Scopus citations


Prostate cancer is one of the leading causes of cancer death in adult men and is a multistage disease with therapeutic challenges of local recurrent advanced tumors and distant metastatic disease. CD44 is a multifunctional and multistructural cell surface glycoprotein that is involved in cell-cell interactions, cell proliferation, and cell migration. In the study, we produced negatively charged and biocompatible hyaluronic acid-based nanoparticles as a therapeutic system for targeting CD44-positive cancer cells. Subsequently, we confirmed the delivery of bioactive epigallocatechin-3-gallate and site-specific inhibition of prostate tumor growth. In this study, hyaluronic acid-based nanoparticles successfully encapsulated epigallocatechin-3-gallate and were efficiently internalized into cancer cells via CD44 ligand receptor recognition, induced cell cycle arrest at G2/M phase, and inhibited prostate cancer cell growth. Furthermore, in vivo assays indicated that these nanoparticles specifically bind CD44 receptors and increase apoptosis of cancer cells, leading to significant decreases in prostate tumor activity and tumor tissue inflammation.

Original languageEnglish (US)
Pages (from-to)30722-30734
Number of pages13
JournalACS Applied Materials and Interfaces
Issue number45
StatePublished - Nov 16 2016


  • CD44
  • epigallocatechin-3-gallate
  • hyaluronic acid
  • nanoparticles
  • prostate cancer

ASJC Scopus subject areas

  • General Materials Science


Dive into the research topics of 'Nanoparticle Targeting CD44-Positive Cancer Cells for Site-Specific Drug Delivery in Prostate Cancer Therapy'. Together they form a unique fingerprint.

Cite this